Showing 1 to 1 of 1 results
forbes.com
🌐 85% Global Worthiness
FDA Receives New Drug Application for Cytisinicline, a Promising Smoking Cessation Drug
Achieve Life Sciences submitted a new drug application to the FDA for cytisinicline, a non-nicotine smoking cessation drug, showing promise in two Phase 3 trials and already approved in the UK, addressing the high rate of smoking-related deaths (over 480,000 annually) in the U.S.
FDA Receives New Drug Application for Cytisinicline, a Promising Smoking Cessation Drug
Achieve Life Sciences submitted a new drug application to the FDA for cytisinicline, a non-nicotine smoking cessation drug, showing promise in two Phase 3 trials and already approved in the UK, addressing the high rate of smoking-related deaths (over 480,000 annually) in the U.S.
Progress
24% Bias Score
Good Health and Well-being
Showing 1 to 1 of 1 results